Recent advances in molecular studies, including the identification of the IDH mutation, 1p/19q co-deletion, H3 K27M mutation, EGFR amplification, TERT promoter mutation, BRAF V600E mutation, MGMT promoter methylation, and others, have revolutionized the diagnosis, classification, and precision chemotherapy of gliomas [5, 8, 9, 14, 19, 24]. Here, BRAF is linked to glioma.